Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cerevel Therapeutics Holdings, Inc. CERE NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
22/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$33.50
-25.5%

Cerevel Therapeutics Holdings, Inc. (CERE) is a Biotechnology company in the Healthcare sector, currently trading at $44.96. It has a SharesGrow Score of 21/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is CERE = $34 (-25.5% upside).

Net income is $433M (loss), growing at -42.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $481M against $674M equity (Debt-to-Equity (D/E) ratio 0.71, moderate). Current ratio is 10.92 (strong liquidity). Debt-to-assets is 38.7%. Total assets: $1.2B.

Analyst outlook: 6 / 16 analysts rate CERE as buy (38%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 40/100 (Fail), Future 16/100 (Fail), Income ?/100 (Fail).

$33.50
▼ 25.49% Downside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Cerevel Therapeutics Holdings, Inc., the average price target is $33.50, with a high forecast of $40.00, and a low forecast of $27.00.
Highest Price Target
$40.00
Average Price Target
$33.50
Lowest Price Target
$27.00

CERE SharesGrow Score Overview

26/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CERE

✗
VALUE Fail
10/100
CERE trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $34, implying -24.4% from the current price $45. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CERE: +0%/yr revenue is, -42.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet CERE: Debt-to-Equity (D/E) ratio 0.71 (moderate), Current ratio is 10.92 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
CERE: Gross margin is 0% (+0 pp trend), $8B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 6 / 16 analysts rate CERE as buy (38%). Analyst consensus target is $34 (-24.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range19.59-44.99
Volume15.03M
Avg Volume (30D)2.06M
Market Cap$8.19B
Beta (1Y)1.41
Share Statistics
EPS (TTM)-2.67
Shares Outstanding$162.06M
IPO Date2020-07-30
Employees355
CEORonald C. Renaud Jr.,
Financial Highlights & Ratios
Gross Profit$-5.63M
EBITDA$-441.64M
Net Income$-432.84M
Operating Income$-447.27M
Total Cash$990.97M
Total Debt$480.78M
Net Debt$-510.19M
Total Assets$1.24B
Price / Earnings (P/E)-16.8
Analyst Forecast
1Y Price Target$33.50
Target High$40.00
Target Low$27.00
Upside-25.5%
Rating ConsensusHold
Analysts Covering16
Buy 38% Hold 63% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS15678U1280

Price Chart

Track all markets on TradingView
CERE
Cerevel Therapeutics Holdings, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
19.59 52WK RANGE 44.99

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 NUVL
NUVL
Nuvalent, Inc.
$105.02
+1.28%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 TVTX
TVTX
Travere Therapeutics, Inc.
$42.13
+37.23%
 SWTX
SWTX
SpringWorks Therapeutics, Inc.
$46.99
+0.02%
 GPCR
GPCR
Structure Therapeutics Inc.
$53.19
-1.95%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message